China Original Largest Manufacturer sales Flumequine CAS42835-25-6 CAS NO.42835-25-6

                                PRODUCT DETAILS       

Flumequine Basic information Product Name: Flumequine Synonyms: 9-Fluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid;Fluoromethylquinoline;Flumequine solution;FLUMEQUINE STANDARD SOLUTION;FLUMEQUINE PESTANAL, 250 MG;FLUMEQUIN;FLUMEQUINE;Fluoromethyl CAS: 42835-25-6 MF: C14H12FNO3 MW: 261.25 EINECS: 255-962-6 Product Categories: FLUGERAL;Pharmaceutical raw material;Aromatics Compounds;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Quinolones and Fluoroquinolones;A - KAntibiotics;Antibacterial;Antibiotics A to;Antibiotics A-FAntibiotics;Chemical Structure Class;Inhibits an EnzymeAntibiotics;Interferes with DNA SynthesisAntibiotics;Mechanism of Action;Spectrum of Activity;API's Mol File: 42835-25-6.mol   Flumequine Chemical Properties Melting point  253-255°C Boiling point  439.7±45.0 °C(Predicted) density  1.45±0.1 g/cm3(Predicted) RTECS  DK1672000 Fp  >110°(230°F) storage temp.  Sealed in dry,Store in freezer, under -20°C solubility  1 M NH4OH: soluble50mg/mL pka pKa 6.42(H2O t=25.0 I=0.025)(Approximate) form  powder color  white to off-white Water Solubility  Soluble in DMSO and dilute alkali hydroxides. Insoluble in water Merck  14,4137 BRN  490724 Stability: Stable. Incompatible with strong oxidizing agents. CAS DataBase Reference 42835-25-6(CAS DataBase Reference) EPA Substance Registry System 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-5-methyl-1-oxo- (42835-25-6)   Safety Information Hazard Codes  Xi Risk Statements  36/37/38 Safety Statements  22-24/25-36/37/39-27-26 WGK Germany  3 F  10 HS Code  29339900 Hazardous Substances Data 42835-25-6(Hazardous Substances Data) MSDS Information Provider Language 9-Fluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid English SigmaAldrich English   Flumequine Usage And Synthesis Description Flumequine is a synthetic antibiotic belonging to the second-generation quinolone group and is mainly active against Gram negative bacteria. It is currently the only non-humans shared broad-spectrum antimicrobial veterinary drug. It is taken as the substitute product of norfloxacin. It has a strong bactericidal activity with excellent efficacy in the treatment of animal bacterial diseases. Its main effect is to inhibit bacterial deoxy nucleic acid (DNA) gyrase, interfering with the deoxyribonucleic acid (DNA) synthesis, thereby causing failure of cell for further division, and thus playing the role of killing bacteria. It is used in bovine, ovine, chicken, rabbits, goats, horses and salmonidae, however the establishment of MRLs was only requested for non-lactating cattle, pigs, sheep, chicken and salmonidae. Chemical Properties White Crystalline Solid Originator Apurone,Riker,France,1977 Uses Flumequine is a fluoroquinolone compound with antimicrobial activity against Gram-negative organisms. It is used in the treatment of enteric infections in food animals and in the treatment of bacterial infections in farmed fish. Flumequine is replacing oxolinic acid in aquaculture because of its more appropriate pharmacokinetic profile and lower effective doses (Treves-Brown 2000). Flumequine also has limited use in humans for the treatment of urinary tract infections. Definition ChEBI: Flumequine is a member of the class of pyridoquinolines that is 1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline carrying additional carboxy, methyl and fluoro substituents at positions 2, 5 and 9 respectively. It is a pyridoquinoline, a 3-oxo monocarboxylic acid, an organofluorine compound and a quinolone antibiotic. Preparation Synthesis: Condensation of 5-fluoro-2-methyltetrahydroquinoline with diethyl ethoxy-methylenemalonate followed by thermal cycli- zation gives ethyl 6,7-dihydro-9-fluoro-5-meth-yl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-car-boxylate,which is saponified with sodium hydroxide to give flumequine. Manufacturing Process 6-Fluoro-2-methyltetrahydroquinoline (32.2 g, 0.2 mol) is mixed with diethyl ethoxymethylenemalonate, and the mixture is heated at 125°C to 130°C for 3 hours. Polyphosphoric acid (200 g) is added, and the solution is gradually heated to 115°C to 120°C in an oil bath with occasional stirring. The temperature is maintained for 1 hour, then the mixture is poured into 600 ml of water and neutralized with 40% sodium hydroxide solution. The product ester which precipitates is separated by filtration, washed with water and suspended in 2 liters of 10% sodium hydroxide solution. The mixture is heated on the steam bath for 1 hour, treated with decolorizing charcoal, filtered, then neutralized with concentrated hydrochloric acid. The solid product is isolated by filtration of the hot solution, washed with water and recrystallized from dimethylformamide. Therapeutic Function Antibacterial Pharmaceutical Applications A tricyclic fluorinated 4-quinolone, with activity similar to that of nalidixic acid in vitro, although it is somewhat more active against some Enterobacteriaceae. Following escalating oral doses of 400, 800 or 1200 mg, mean peak plasma levels reached at 2 h are 13.5, 23.8 and 31.9 mg/L, respectively. The apparent elimination half-life is about 7 h. The main metabolite, hydroxyflumequine, is much more rapidly eliminated. About 60% of a dose appears in the urine, mostly in the form of conjugates. Urinary concentrations following an 800 mg dose are 10–35 mg/L, with a peak of 105 mg/L. It has no effect on the pharmacokinetics of theophylline. Flumequine is generally well tolerated, side effects being mainly mild gastrointestinal tract disturbances, rashes, dizziness and confusion. It is principally used in uncomplicated urinary tract infections.   Flumequine Preparation Products And Raw materials Raw materials Sodium hydroxide-->Polyphosphoric acid-->Diethyl ethoxymethylenemalonate-->ethyl 9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylate-->6-Fluoro-1,2,3,4-tetrahydro-2-methylquinoline

                                                                         About US 

Leader Biochemical Group is a large leader incorporated industry manufacturers and suppliers of advanced refined raw materials From the year of 1996 when our factory was put into production to year of 2020, our group has successively invested in more than 52 factories with shares and subordinates.We focus on manufacture Pharm & chemicals, functional active ingredients, nutritional Ingredients, health care products, cosmetics, pharmaceutical and refined feed, oil, natural plant ingredients industries to provide top quality of GMP standards products.All the invested factories' product lines cover API and intermediates, vitamins, amino acids, plant extracts, daily chemical products, cosmetics raw materials, nutrition and health care products, food additives, feed additives, essential oil products, fine chemical products and agricultural chemical raw materials And flavors and fragrances. Especially in the field of vitamins, amino acids, pharmaceutical raw materials and cosmetic raw materials, we have more than 20 years of production and sales experience. All products meet the requirements of high international export standards and have been recognized by customers all over the world. Our manufacture basement & R&D center located in National Aerospace Economic & Technical Development Zone Xi`an Shaanxi China. Now not only relying on self-cultivation and development as well as maintains good cooperative relations with many famous research institutes and universities in China. Now, we have closely cooperation with Shanghai Institute of Organic Chemistry of Chinese Academy of Science, Beijing Institute of Material Medical of Chinese Academy of Medical Science, China Pharmaceutical University, Zhejiang University. Closely cooperation with them not only integrating Science and technology resources, but also increasing the R&D speed and improving our R&D power. Offering Powerful Tech supporting Platform for group development. Keep serve the manufacture and the market as the R&D central task, focus on the technical research.  Now there are 3 technology R & D platforms including biological extract, microorganism fermentation and chemical synthesis, and can independently research and develop kinds of difficult APIs and pharmaceutical intermediates. With the strong support of China State Institute of Pharmaceutical Industry (hereinafter short for CSIPI), earlier known as Shanghai Institute of Pharmaceutical Industry (SIPI), we have unique advantages in the R & D and industrialization of high-grade, precision and advanced products.  Now our Group technical force is abundant, existing staff more that 1000 people, senior professional and technical staff accounted for more than 50% of the total number of employees, including 15 PhD research and development personnel, 5 master′ S degree in technical and management personnel 9 people. We have advanced equipment like fermentation equipment and technology also extraction, isolation, purification, synthesis with rich production experience and strict quality control system, According to the GMP required, quickly transforming the R&D results to industrial production in time, it is our advantages and our products are exported to North and South America, Europe, Middle East, Africa, and other five continents and scale the forefront in the nation, won good international reputation.  We believe only good quality can bring good cooperation, quality is our key spirit during our production, we are warmly welcome clients and partner from all over the world contact us for everlasting cooperation, Leader will be your strong, sincere and reliable partner in China.

                                                                      Our Group profiles

Our Factories production lines

                                                   Our Factories R&D ability

                        Our Factories warehouse 

                                                       Product information

Flumequine Basic information Product Name: Flumequine Synonyms: 9-Fluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid;Fluoromethylquinoline;Flumequine solution;FLUMEQUINE STANDARD SOLUTION;FLUMEQUINE PESTANAL, 250 MG;FLUMEQUIN;FLUMEQUINE;Fluoromethyl CAS: 42835-25-6 MF: C14H12FNO3 MW: 261.25 EINECS: 255-962-6 Product Categories: FLUGERAL;Pharmaceutical raw material;Aromatics Compounds;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Quinolones and Fluoroquinolones;A - KAntibiotics;Antibacterial;Antibiotics A to;Antibiotics A-FAntibiotics;Chemical Structure Class;Inhibits an EnzymeAntibiotics;Interferes with DNA SynthesisAntibiotics;Mechanism of Action;Spectrum of Activity;API's Mol File: 42835-25-6.mol   Flumequine Chemical Properties Melting point  253-255°C Boiling point  439.7±45.0 °C(Predicted) density  1.45±0.1 g/cm3(Predicted) RTECS  DK1672000 Fp  >110°(230°F) storage temp.  Sealed in dry,Store in freezer, under -20°C solubility  1 M NH4OH: soluble50mg/mL pka pKa 6.42(H2O t=25.0 I=0.025)(Approximate) form  powder color  white to off-white Water Solubility  Soluble in DMSO and dilute alkali hydroxides. Insoluble in water Merck  14,4137 BRN  490724 Stability: Stable. Incompatible with strong oxidizing agents. CAS DataBase Reference 42835-25-6(CAS DataBase Reference) EPA Substance Registry System 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-5-methyl-1-oxo- (42835-25-6)   Safety Information Hazard Codes  Xi Risk Statements  36/37/38 Safety Statements  22-24/25-36/37/39-27-26 WGK Germany  3 F  10 HS Code  29339900 Hazardous Substances Data 42835-25-6(Hazardous Substances Data) MSDS Information Provider Language 9-Fluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid English SigmaAldrich English   Flumequine Usage And Synthesis Description Flumequine is a synthetic antibiotic belonging to the second-generation quinolone group and is mainly active against Gram negative bacteria. It is currently the only non-humans shared broad-spectrum antimicrobial veterinary drug. It is taken as the substitute product of norfloxacin. It has a strong bactericidal activity with excellent efficacy in the treatment of animal bacterial diseases. Its main effect is to inhibit bacterial deoxy nucleic acid (DNA) gyrase, interfering with the deoxyribonucleic acid (DNA) synthesis, thereby causing failure of cell for further division, and thus playing the role of killing bacteria. It is used in bovine, ovine, chicken, rabbits, goats, horses and salmonidae, however the establishment of MRLs was only requested for non-lactating cattle, pigs, sheep, chicken and salmonidae. Chemical Properties White Crystalline Solid Originator Apurone,Riker,France,1977 Uses Flumequine is a fluoroquinolone compound with antimicrobial activity against Gram-negative organisms. It is used in the treatment of enteric infections in food animals and in the treatment of bacterial infections in farmed fish. Flumequine is replacing oxolinic acid in aquaculture because of its more appropriate pharmacokinetic profile and lower effective doses (Treves-Brown 2000). Flumequine also has limited use in humans for the treatment of urinary tract infections. Definition ChEBI: Flumequine is a member of the class of pyridoquinolines that is 1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline carrying additional carboxy, methyl and fluoro substituents at positions 2, 5 and 9 respectively. It is a pyridoquinoline, a 3-oxo monocarboxylic acid, an organofluorine compound and a quinolone antibiotic. Preparation Synthesis: Condensation of 5-fluoro-2-methyltetrahydroquinoline with diethyl ethoxy-methylenemalonate followed by thermal cycli- zation gives ethyl 6,7-dihydro-9-fluoro-5-meth-yl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-car-boxylate,which is saponified with sodium hydroxide to give flumequine. Manufacturing Process 6-Fluoro-2-methyltetrahydroquinoline (32.2 g, 0.2 mol) is mixed with diethyl ethoxymethylenemalonate, and the mixture is heated at 125°C to 130°C for 3 hours. Polyphosphoric acid (200 g) is added, and the solution is gradually heated to 115°C to 120°C in an oil bath with occasional stirring. The temperature is maintained for 1 hour, then the mixture is poured into 600 ml of water and neutralized with 40% sodium hydroxide solution. The product ester which precipitates is separated by filtration, washed with water and suspended in 2 liters of 10% sodium hydroxide solution. The mixture is heated on the steam bath for 1 hour, treated with decolorizing charcoal, filtered, then neutralized with concentrated hydrochloric acid. The solid product is isolated by filtration of the hot solution, washed with water and recrystallized from dimethylformamide. Therapeutic Function Antibacterial Pharmaceutical Applications A tricyclic fluorinated 4-quinolone, with activity similar to that of nalidixic acid in vitro, although it is somewhat more active against some Enterobacteriaceae. Following escalating oral doses of 400, 800 or 1200 mg, mean peak plasma levels reached at 2 h are 13.5, 23.8 and 31.9 mg/L, respectively. The apparent elimination half-life is about 7 h. The main metabolite, hydroxyflumequine, is much more rapidly eliminated. About 60% of a dose appears in the urine, mostly in the form of conjugates. Urinary concentrations following an 800 mg dose are 10–35 mg/L, with a peak of 105 mg/L. It has no effect on the pharmacokinetics of theophylline. Flumequine is generally well tolerated, side effects being mainly mild gastrointestinal tract disturbances, rashes, dizziness and confusion. It is principally used in uncomplicated urinary tract infections.   Flumequine Preparation Products And Raw materials Raw materials Sodium hydroxide-->Polyphosphoric acid-->Diethyl ethoxymethylenemalonate-->ethyl 9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylate-->6-Fluoro-1,2,3,4-tetrahydro-2-methylquinoline